Novel antimicrobial peptide derived from pse-t2 peptide and use thereof
The Pse-T2 variant, characterized by amino acid deletions, addresses bacterial resistance by enhancing antibacterial activity and stability, effectively targeting antibiotic-resistant bacteria with low cytotoxicity, thus overcoming the limitations of existing antibiotics.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- IND ACADEMIC COOP FOUND YONSEI UNIV
- Filing Date
- 2025-12-02
- Publication Date
- 2026-06-11
AI Technical Summary
Bacterial resistance to antibiotics is a significant clinical concern, necessitating the development of new antibiotics that can effectively target resistant bacteria and function independently of autolysin activity, as existing antibiotics face challenges due to rapid bacterial resistance development and tolerance mechanisms.
A Pse-T2 variant is developed by deleting specific amino acid residues from the Pse-T2 peptide, enhancing in vivo stability and antibacterial activity while maintaining low cytotoxicity and erythrocyte hemolytic activity, utilizing a method that includes culturing recombinant cells and recovering the variant.
The Pse-T2 variant exhibits strong antibacterial activity against both Gram-negative and Gram-positive bacteria, including antibiotic-resistant strains, with reduced cytotoxicity and improved stability, effectively treating infections caused by multidrug-resistant bacteria.
Smart Images
Figure 1 Figure 2